Published Aug 15, 2026
Beam Therapeutics Q2 FY2026: First Pivotal Dose In, Risto-cel BLA on Track, and a $1.2B Balance Sheet Reset
In-depth research on BEAM covering the business overview, key financial moves, risk frame, and the bottom-line on what changed since the last report.
4,553 words20 min read
Read report